Published in Oncogene on August 06, 2007
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol (2010) 7.73
Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One (2009) 3.89
Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer (2010) 2.20
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell (2009) 2.15
The tumor microenvironment and metastatic disease. Clin Exp Metastasis (2008) 1.91
c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol (2011) 1.81
Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene (2012) 1.62
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer (2010) 1.56
MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer (2009) 1.48
Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 1.45
Wnt signaling and colon carcinogenesis: beyond APC. J Carcinog (2011) 1.44
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer (2010) 1.14
Dysregulated pH in Tumor Microenvironment Checkmates Cancer Therapy. Bioimpacts (2013) 1.11
Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo. Neoplasia (2009) 1.10
Expression of the c-Met Proteins in Malignant Skin Cancers. Ann Dermatol (2011) 1.09
Semaphorin 4D regulates gonadotropin hormone-releasing hormone-1 neuronal migration through PlexinB1-Met complex. J Cell Biol (2008) 1.09
MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines. Br J Cancer (2011) 1.06
EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis. Cancer Res (2013) 0.99
The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments. Mol Biol Cell (2012) 0.91
Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth. Oncogene (2010) 0.86
cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. J Cancer (2014) 0.84
The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor. J Pharmacol Exp Ther (2010) 0.84
MicroRNA and MET in lung cancer. Ann Transl Med (2015) 0.84
Prognostic and predictive value of MET deregulation in non-small cell lung cancer. Ann Transl Med (2015) 0.81
Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies. J Thyroid Res (2011) 0.81
The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer. Curr Signal Transduct Ther (2011) 0.79
MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers. Clin Exp Metastasis (2009) 0.77
c-MET: an exciting new target for anticancer therapy. Ther Adv Med Oncol (2011) 0.77
MET receptor is a potential therapeutic target in high grade cervical cancer. Oncotarget (2015) 0.76
Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma. Oncogene (2016) 0.75
Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/MET Pathway. PLoS One (2016) 0.75
Comment on "Effect of transferred NK4 gene on proliferation, migration, invasion, and apoptosis of human prostate cancer DU145 cells" by Dan Yue et al. in Asian Journal of Andrology. Asian J Androl (2010) 0.75
Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases. Mol Diagn Ther (2017) 0.75
Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell (1999) 5.07
Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol (1992) 5.04
Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol Cell Biol (1995) 4.60
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell (1994) 4.10
Rous sarcoma virus-transformed fibroblasts adhere primarily at discrete protrusions of the ventral membrane called podosomes. Exp Cell Res (1985) 3.41
Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene (1991) 3.41
Tyrosine kinase receptor indistinguishable from the c-met protein. Nature (1989) 3.00
Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res (1995) 2.84
Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature (1998) 2.83
Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J (1992) 2.65
A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell (2001) 2.62
Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J Cell Biol (1997) 2.51
Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene (1991) 2.44
Plexin A is a neuronal semaphorin receptor that controls axon guidance. Cell (1998) 2.39
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene (2000) 2.27
Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. Cell (1996) 2.14
HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death. EMBO J (1996) 2.09
Concordance between telepathologic diagnosis and conventional histopathologic diagnosis: a multiobserver store-and-forward study on 20 skin specimens. Arch Dermatol (2002) 2.07
Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem (1995) 2.06
RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J (1994) 2.04
Detection of phosphotyrosine-containing proteins in the detergent-insoluble fraction of RSV-transformed fibroblasts by azobenzene phosphonate antibodies. EMBO J (1984) 1.98
Monoclonal antibodies against murine gamma interferon. Proc Natl Acad Sci U S A (1984) 1.95
The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer (1991) 1.95
Biosynthesis of the protein encoded by the c-met proto-oncogene. Oncogene (1989) 1.92
Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol (2006) 1.91
The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. Mol Cell Biol (1991) 1.90
Cell surface molecules and fibronectin-mediated cell adhesion: effect of proteolytic digestion of membrane proteins. J Cell Biol (1982) 1.90
Signalling by semaphorin receptors: cell guidance and beyond. Trends Cell Biol (2000) 1.89
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem (2008) 1.88
Cleavage of a 135 kD cell surface glycoprotein correlates with loss of fibroblast adhesion to fibronectin. Exp Cell Res (1985) 1.86
Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene (1994) 1.81
Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene (2007) 1.79
Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci (1998) 1.75
Overexpression of the RON gene in human breast carcinoma. Oncogene (1998) 1.73
Cross-talk between the proto-oncogenes Met and Ron. Oncogene (2000) 1.71
The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. J Biol Chem (1991) 1.71
A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. Proc Natl Acad Sci U S A (1992) 1.70
The transmembrane protein Off-track associates with Plexins and functions downstream of Semaphorin signaling during axon guidance. Neuron (2001) 1.68
Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol (1996) 1.67
The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene (1995) 1.66
A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol (1996) 1.65
Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes. EMBO J (1997) 1.60
c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. Oncogene (1991) 1.58
A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth. Oncogene (2006) 1.56
Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene. Proc Natl Acad Sci U S A (1993) 1.56
Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br J Cancer (1993) 1.55
C-terminal truncated forms of Met, the hepatocyte growth factor receptor. Mol Cell Biol (1991) 1.53
Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchanger. J Biol Chem (1993) 1.51
Granular cell ameloblastoma: a case report with histochemical findings. Eur J Cancer B Oral Oncol (1996) 1.49
A 135,000 molecular weight plasma membrane glycoprotein involved in fibronectin-mediated cell adhesion. Immunofluorescence localization in normal and RSV-transformed fibroblasts. Exp Cell Res (1986) 1.48
Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. J Biol Chem (1991) 1.48
Plexin signaling hampers integrin-based adhesion, leading to Rho-kinase independent cell rounding, and inhibiting lamellipodia extension and cell motility. FASEB J (2004) 1.46
Induction of apoptosis of human primary osteoclasts treated with a transcription factor decoy mimicking a promoter region of estrogen receptor alpha. Apoptosis (2005) 1.46
A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor. Mol Cell Biol (1993) 1.44
The tyrosine kinase receptors Ron and Sea control "scattering" and morphogenesis of liver progenitor cells in vitro. Mol Biol Cell (1996) 1.42
HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol (1999) 1.41
Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res (1995) 1.40
Morphometric analysis of AgNORs in uveal malignant melanoma. Anal Quant Cytol Histol (1998) 1.39
A primary, lateral-cervical medullary thyroid carcinoma: a case report. J Clin Endocrinol Metab (1996) 1.38
The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene (1995) 1.38
Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci U S A (1996) 1.37
Overexpression of the Met/HGF receptor in ovarian cancer. Int J Cancer (1994) 1.36
Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer (1996) 1.35
Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. Oncogene (1997) 1.34
Transcatheter closure of persistent ductus arteriosus with the Amplatzer duct occluder in very young symptomatic children. Heart (2004) 1.31
A natural hepatocyte growth factor/scatter factor autocrine loop in myoblast cells and the effect of the constitutive Met kinase activation on myogenic differentiation. J Cell Biol (1997) 1.30
Antibacterial activity of pure flavonoids isolated from mosses. Phytochemistry (1999) 1.30
Fibronectin-plasma membrane interaction in the adhesion of hemopoietic cells. J Cell Biol (1986) 1.29
Clinically equivocal melanocytic skin lesions with features of regression: a dermoscopic-pathological study. Br J Dermatol (2004) 1.27
Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF. J Biol Chem (1994) 1.26
Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene (1996) 1.25
The hyaluronate receptor is identical to a glycoprotein of Mr 85,000 (gp85) as shown by a monoclonal antibody that interferes with binding activity. J Biol Chem (1987) 1.24
p145, a protein with associated tyrosine kinase activity in a human gastric carcinoma cell line. Mol Cell Biol (1988) 1.22
Specific uncoupling of GRB2 from the Met receptor. Differential effects on transformation and motility. J Biol Chem (1996) 1.22
Targeting of the SF/HGF receptor to the basolateral domain of polarized epithelial cells. J Cell Biol (1994) 1.22
Pathway specificity for Met signalling. Nat Cell Biol (2001) 1.19
Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer (1996) 1.18
Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Res (2001) 1.18
Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells. Mol Cell Biol (1986) 1.17
Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene (2000) 1.15
Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase. J Biol Chem (1994) 1.15
Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene. Cell Mol Biol (Noisy-le-grand) (1994) 1.15
Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. Cancer Genet Cytogenet (1992) 1.14
Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene (1999) 1.14
Diagnostic and prognostic implications of the World Health Organization classification of neuroendocrine tumors. J Endocrinol Invest (2008) 1.14
A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. Proc Natl Acad Sci U S A (1996) 1.14
Accelerated bone mass senescence after hematopoietic stem cell transplantation. Transl Med UniSa (2013) 1.13
Constitutive activation of the RON gene promotes invasive growth but not transformation. Mol Cell Biol (1996) 1.13
HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB J (2000) 1.13